154_CD GlaxoSmithKline_NNP Financial_NNP record_NN Quarterly_JJ trend_NN An_DT unaudited_JJ analysis_NN is_VBZ provided_VBN by_IN quarter_NN of_IN the_DT Group_NNP results_NNS in_IN sterling_NN for_IN the_DT financial_JJ year_NN 2004_CD ._.
The_DT analysis_NN comprises_VBZ statutory_JJ results_NNS ,_, business_NN performance_NN results_NNS and_CC pharmaceutical_JJ sales_NNS by_IN therapeutic_JJ area_NN ._.
160_CD GlaxoSmithKline_NNP Financial_NNP record_NN Five_CD year_NN record_NN A_DT record_NN of_IN financial_JJ performance_NN is_VBZ provided_VBN analyzed_VBN in_IN accordance_NN with_IN current_JJ reporting_NN practice_NN ._.
Merger_NN ,_, restructuring_NN and_CC disposal_NN of_IN subsidiaries_NNS Manufacturing_NNP and_CC other_JJ restructuring_NN 83 121 162 171_CD Merger_NN costs_NNS and_CC product_NN divestments_NNS 286_CD 840_CD 1,069_CD 895_CD Other_JJ items_NNS 21_CD 50_CD 421_CD 22_CD Loss_NN profit_NN before_IN taxation_NN 390_CD 1,011_CD 1,652_CD 702_CD Loss_NN profit_NN attributable_JJ to_TO shareholders_NNS 281_CD 712_CD 1,330_CD 452_CD Business_NN performance_NN results_NNS Turnover_NN 20,359_CD 21,441_CD 21,212_CD 20,489_CD 18,079_CD R&D_NNP expenditure_NN 2,839_CD 2,770_CD 2,732_CD 2,555_CD 2,510_CD per_IN cent_NN of_IN sales_NNS 14_CD %_NN 13_CD %_NN 13_CD %_NN 12_CD %_NN 14_CD %_NN Trading_NN profit_NN 6,150_CD 6,904_CD 6,712_CD 6,041_CD 5,061_CD per_IN cent_NN of_IN sales_NNS 30_CD %_NN 32_CD %_NN 32_CD %_NN 30_CD %_NN 28_CD %_NN Net_JJ interest_NN payable_JJ 203 161 141_CD 88_CD 182_CD profit_NN before_IN taxation_NN 6,119_CD 6,703_CD 6,535_CD 6,157_CD 5,362_CD Adjusted_VBN earnings_NNS profit_NN attributable_JJ to_TO shareholders_NNS 4,302_CD 4,759_CD 4,642_CD 4,371_CD 3,686_CD During_IN the_DT years_NNS 2000_CD to_TO 2003_CD ,_, business_NN performance_NN was_VBD the_DT primary_JJ performance_NN measure_NN used_VBN by_IN management_NN and_CC was_VBD presented_VBN after_IN excluding_VBG merger_NN items_NNS ,_, integration_NN and_CC restructuring_NN costs_NNS and_CC disposals_NNS of_IN business_NN ._.
Management_NNP believes_VBZ that_IN exclusion_NN of_IN these_DT items_NNS provides_VBZ a_DT better_JJR comparison_NN of_IN the_DT way_NN in_IN which_WDT the_DT business_NN was_VBD managed_VBN and_CC gives_VBZ an_DT indication_NN of_IN the_DT performance_NN of_IN the_DT Group_NNP in_IN terms_NNS of_IN those_DT elements_NNS of_IN revenue_NN and_CC expenditure_NN which_WDT local_JJ management_NN was_VBD able_JJ to_TO inuence_NN ._.
This_DT information_NN ,_, which_WDT is_VBZ provided_VBN in_IN addition_NN to_TO the_DT statutory_JJ results_NNS prepared_VBN under_IN UK_NNP GAAP_NNP ,_, is_VBZ given_VBN to_TO assist_VB shareholders_NNS to_TO gain_VB a_DT clearer_JJR understanding_NN of_IN the_DT underlying_VBG performance_NN of_IN the_DT business_NN and_CC to_TO increase_VB comparability_NN for_IN the_DT periods_NNS presented_VBN ._.
Statutory_JJ results_NNS include_VBP these_DT items_NNS ._.
For_IN 2004_CD ,_, with_IN the_DT completion_NN of_IN these_DT programs_NNS ,_, the_DT Group_NNP is_VBZ reporting_VBG results_NNS on_IN a_DT statutory_JJ basis_NN only_RB ._.
2004 2003 2002 2001_CD 2000_CD Amounts_NNS in_IN accordance_NN with_IN US_NNP GAAP_NNP m_FW m_FW m_FW m_FW m_FW Turnover_NN 19,986_CD 21,117_CD 21,212_CD 20,489_CD 9,559_CD Net_JJ income_NN loss_NN 2,732_CD 2,420_CD 413_CD 143_CD 5,228_CD Basic_JJ net_JJ income_NN loss_NN per_IN share_NN pence_NN 47.6_CD 41.7_CD p_NN 7.0_CD p_NN 2.4_CD p_VBP 145.6_CD p_JJ Diluted_JJ net_JJ income_NN loss_NN per_IN share_NN pence_NN 47.5_CD 41.6_CD p_NN 7.0_CD p_NN 2.4_CD p_VBP 145.6_CD p_JJ The_DT information_NN below_IN presents_NNS US_NNP GAAP_NNP net_JJ income_NN loss_NN and_CC net_JJ income_NN loss_NN per_IN share_NN as_IN if_IN the_DT results_NNS for_IN the_DT years_NNS ended_VBN 31st_CD December_NNP 2000_CD and_CC 2001_CD were_VBD adjusted_VBN to_TO reverse_VB the_DT amortisation_NN expense_NN for_IN goodwill_NN and_CC indefinite-lived_JJ intangible_JJ assets_NNS ,_, that_DT is_VBZ ,_, as_IN if_IN SFAS_NNP 142_CD had_VBD also_RB applied_VBN in_IN those_DT years_NNS ._.
It_PRP excludes_VBZ those_DT employees_NNS who_WP are_VBP employed_VBN and_CC managed_VBN by_IN GlaxoSmithKline_NNP on_IN a_DT contract_NN basis_NN ._.
Exchange_NNP rates_NNS As_IN a_DT guide_NN to_TO holders_NNS of_IN ADRs_NNS ,_, the_DT following_VBG tables_NNS set_VBN out_RP ,_, for_IN the_DT periods_NNS indicated_VBD ,_, information_NN on_IN the_DT exchange_NN rate_NN of_IN US_NNP dollars_NNS for_IN sterling_NN as_IN reported_VBN by_IN the_DT Federal_NNP Reserve_NNP Bank_NNP of_IN New_NNP York_NNP noon_NN buying_NN rate_NN ._.
Average_JJ 1.84_CD 1.63_CD 1.51_CD 1.44_CD 1.51_CD The_DT average_JJ rate_NN for_IN the_DT year_NN is_VBZ calculated_VBN as_IN the_DT average_NN of_IN the_DT noon_NN buying_NN rates_NNS on_IN the_DT last_JJ day_NN of_IN each_DT month_NN during_IN the_DT year_NN ._.
